Wells Fargo’s Lexeo Therapeutics LXEO Stock Holding History
Bought
Maintained
Sold
Other funds holding LXEO
Wells Fargo's LXEO Position: Q3 2026 in Review
Wells Fargo reduced its Lexeo Therapeutics (LXEO) stake by 77% in Q3 2026, selling an estimated $206K and leaving 13,783 shares worth $46.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5544.
Wells Fargo first reported a position in LXEO in Q4 2023 and has held it in 12 quarters since. The position peaked at $702K in Q4 2025. 153 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.
- Wells Fargo held 13,783 shares of Lexeo Therapeutics worth $46.6K as of Q3 2026.
- Wells Fargo sold 45,582 Lexeo Therapeutics shares in Q3 2026, an estimated $206K.
- Lexeo Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #5544 holding.
- Wells Fargo first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 12 quarters since.
- Wells Fargo's Lexeo Therapeutics position peaked at $702K in Q4 2025.
- 153 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.
Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.